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Breast cancer development, as in other types of tumours, is thought
to be the result of the unmasking of one or more recessive tumour
suppressor genes by somatic alterations (Knudson, 1985). Three
familial forms of breast cancer, caused by mutations of the BRCA1,
BRCA2 and TP53 genes, are the prototypes for this kind of
carcinogenesis. Among tumours from patients with inherited
BRCA1 and BRCA2 mutations, over 90% have lost the wild-type
alleles (Neuhausen and Marshall, 1994; Gudmundsson et al, 1995);
however, both susceptibility genes are infrequent targets for
somatic inactivation in sporadic breast cancer (Lancaster et al,
1996). TP53 is another gene that, within the Li–Fraumeni
syndrome, also is responsible for an inherited predisposition to
breast cancer (Sidransky et al, 1992). The p53 gene is mutated in
about 22–27% of sporadic breast tumours (Sjögren et al, 1996).
Several studies have been published in an effort to estimate the
frequency of somatic loss of wild-type TP53 alleles, before it was
understood that point mutated p53 could have a dominant-negative
action (Milner and Medcalf, 1991) and therefore could modify cell
functions even if one allele alone was affected. Most of these
reports had initially used the highly informative YNZ22.1 (D17S5)
marker, thought to map close to TP53, on the short arm of chromo-
some 17. It later became clear that the D17S5 locus is actually
located on band 17p13.3, approximately 20 cM distal to the TP53
gene (Coles et al, 1990). At this locus, a high frequency of allelic
losses (as high as 60%) has been detected in sporadic (Mackay et
al, 1988) as well as in familial breast tumours (Lindblom et al,
1993). In breast carcinomas 17p13.3 loss of heterozygosity (LOH)
is independent of TP53 point mutations and is associated with a
high S phase index (Merlo et al, 1994). A previous report on a panel
of primary tumours from stage I–IV breast cancer patients have
shown than LOH of D17S5 is associated with disease-free survival
(Nagai et al, 1994). The general hypothesis being tested in our
study is that allele losses at a specific chromosome location, framed
by a well-mapped set of markers, could be associated with the clin-
ical course of breast cancer. Specifically, a positive association with
17p13.3-ter LOH would provide further evidence for the existence,
in this locus, of a tumour suppressor gene whose mutation
conferred a more aggressive phenotype.
MATERIALS AND METHODS
Patients and tumour samples
Between April 1987 and November 1991 160 primary breast
carcinomas were removed surgically by either mastectomy or
lumpectomy from untreated patients with stage I, II and III disease
at the S Giovanni Vecchio Hospital, Torino, Italy. Following histo-
logical diagnosis made on frozen sections, tumour samples were
dissected quickly to remove most of normal tissue and stored at
–80°C. Peripheral blood was collected for all the patients whose
tumour was genetically analysed. A total of 152 patients fulfilled
the criteria for inclusion in this study; eight patients that had
developed a second carcinoma in the contralateral breast were not
considered eligible and were withdrawn. Thirty-nine patients
received adjuvant chemotherapy (CT) according to the Milan
protocol (Bonadonna et al, 1986). Most of the tumours were infil-
trating ductal carcinomas (n = 132), 16 tumours were infiltrating
lobular carcinomas, 3 were mucinous and one a medullary
carcinoma. The median follow-up duration time was 6.1 (range
0.7–8.6) years.
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All probes used in this study were as follows: D17S5 (Nakamura
et al, 1988) and D17S379 (Carrozzo and Ledbetter, 1993) were the
two proximal markers; D17S34 (Isomura et al, 1994) and ABR
(Heisterkamp et al, 1993) were the more telomeric markers. The
physical distance between these loci has been estimated to be
3 Mb (Figure 1). ABR has been mapped 250 Kb proximal to
D17S34 (Stack et al, 1995). Probe YNZ22.1 detects the D17S5
VNTR polymorphisms on Southern blots with PstI and BamHI
digested genomic DNA; the 144D6 probe detects the D17S34
VNTR on RsaI digested DNA. The ABR-VNTR1 polymorphism
was detected on BamI digested DNA. Southern blot and
microsatellite analyses were performed as previously described
(Stack et al, 1995). In 17 cases in which D17S5 was heterozygous
but LOH needed to be confirmed and in a number of uninforma-
tive samples, the D17S379 microsatellite marker was used.
D17S379 is linked to D17S5 but is located 200 Kbp proximal (R
Carrozzo, personal communication). Tumour/normal products
were run in adjacent gel tracks and relative allele intensities were
visually compared independently by two individuals. A loss of
signal relative to one of the alleles indicated a LOH. In most cases,
however, the LOH was not complete and an obvious reduction in
intensity of one allele in the tumoural DNA relative to the intensity
of normal DNA was observed. This condition has been called
allele imbalance; however, for clarity in the present report the term
loss of heterozygosity will be used to indicate both of these events.
Marginal imbalances and unequal copy number due to amplifica-
tion were excluded from the statistical analyses.
TP53 mutation analysis
Polymerase chain reaction (PCR) amplification of exons 5, 6, 7
and 8 covering the highly conserved regions of TP53, was
performed with specific primers designed from the flanking
intronic sequence of each exon. Mutations were detected by
single-strand conformation polymorphism (SSCP) analysis as
previously reported (Merlo et al, 1994).
Cell kinetics
S-phase index was measured by an in vitro 5-bromo-2´deoxy-
uridine (BrdU) uptake analysis, as previously reported (Merlo et
al, 1994). Oestrogen receptors (ER) and Ki-67 immunostaining
was performed on frozen sections with an anti-Ki-67 (Dako
S.p.A., Milano, Italy) anti-ER (Abbott Laboratories, Chicago, IL,
USA) antibodies according to manufacturers’ instructions. For all
immunohistochemical reactions the ABC complex method was
used (Vector Laboratories, Burlingame, CA, USA) according with
standard procedures.
Statistical analysis
To group breast tumours into a low and high proliferation rank we
used the median values both for BrdU incorporation and Ki-67
staining. These values were calculated on a data set of over 1000
tumours and were 7.5% and 9.5% for BrdU and Ki-67 respec-
tively; ER cut-off value for positivity was set to 10% stained
nuclei. In the analysis of relapse-free survival, second primary
cancers and deaths due to other causes were not considered events.
Differences in subsets in Kaplan–Meier plots and univariate prob-
abilities were evaluated by log-rank test. Multivariate analyses for
disease-free survival (DFS) and overall survival (OS) were
performed to fit a Cox proportional hazards model (Cox, 1972). A
backward stepwise covariate selection was used to identify the
most significant prognostic factors, with variables being elimi-
nated by the maximum likelihood estimate.
RESULTS
Genetic analysis
DNA samples from primary breast carcinomas of 152 patients
with complete follow-up records were tested for genetic alter-
ations on chromosome 17p. Point mutation analysis by SSCP of
the TP53 gene was possible in 90 of these tumours. Twenty-five
tumours were found to have a mutated TP53 gene (27.8%). To
detect allele losses in the 17p13.3–17pter region four polymorphic
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Table 1 Association between LOH at proximal and distal markers of the
17p13.3 chromosome
D17S5/ D17S379
Normal LOH
D17S34/ABR n (%)a n (%)a
Normal 43 (75.4) 14 (24.6)
P = 0.00001b
LOH 9 (25.7) 26 (74.3)
aRow percentages. bBy c2 analysis.
Table 2 Association between breast cancer clinicopathological variables
and genetic alterations of chromosome 17p13.3
17p13.3 Normal 17p13.3 LOH
Variable n (%)a n (%)a P-valueb
T (≤ 2 cm) 36 (63.2) 21 (36.8)
0.1 T (> 2 cm) 42 (48.8) 44 (51.2)
N– 34 (52.3) 31 (47.7)
0.5 N+ 44 (58.7) 31 (41.3)
Grade I 4 (80.0) 1 (20.0)
II 40 (56.3) 31 (43.7) 0.1
III 20 (43.5) 26 (56.5)
Stage I 17 (58.6) 12 (41.4)
II 58 (54.2) 49 (45.8) 0.6
III 3 (75.0) 1 (25.0)
Adjuvant CT– 59 (54.6) 49 (45.4)
0.9 Adjuvant CT+ 19 (54.3) 16 (45.7)
ER– 48 (56.5) 37 (43.5)
1.0 ER+ 27 (55.1) 22 (44.9)
BrdU
Low 45 (65.2) 24 (34.8)
0.02 High 33 (45.2) 40 (54.8)
Ki-67
Low 34 (56.7) 26 (43.3)
0.8 High 41 (53.2) 36 (46.8)
TP53
Wild-type 36 (55.4) 29 (44.6)
0.3 Mutated 10 (41.7) 14 (58.3)
aRow percentages. bBy c2 analysis. cT: tumour size; N: lymph nodes; ER:
oestrogen receptors.
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]loci were examined in the tumour DNA, along with their matching
normal lymphocyte DNA. All of the tumours that were found to be
deleted at the D17S5 locus showed loss of the D17S379 marker.
Due to the lower informativeness compared to D17S5, D17S379
did not provide any additional information on the genomic status
of the proximal boundary of the 17p13.3 region. Only in one case
was D17S379 found to be deleted while D17S5 was uninformative
(Figure 2). Sixty-five of 143 heterozygous tumours had lost at
least one of the markers at the minimum region of loss (45%).
Associations
Our results indicate that the 17p13.3-ter region bordered by loci
D17S5/D17S379 and D17S34/ABR is frequently affected by LOH
that is independent of point mutation in the P53 gene. To validate the
use D17S5/D17S379 and D17S34/ABR for the identification of
LOH in a common region of deletion, we tested for the levels of asso-
ciation of losses detected by the centromeric and telomeric markers.
The association between D17S5/D17S379 and D17S34/ABR LOHs
was highly significant (P = 0.00001). In fact, 74.3% of the tumours
that had lost the proximal markers had also lost the telomeric poly-
morphism (Table 1). We were unable to demonstrate any association
between LOH of 17p13.3-ter and tumour size, lymph node status,
tumour grade, oestrogen receptors, and expression of the cell cycle
associated nuclear antigen Ki-67 (Table 2). This later observation is
in contrast with the significant relationship observed with the BrdU
index (P = 0.02), suggesting that chromosome 17p13.3 LOH affects
more specifically the S phase of cell cycle. As previously reported
(Merlo et al, 1994) a lack of association between LOH of markers on
17p13.3-ter and mutations of the TP53 gene was observed. These
data support the belief that in a great proportion of primary breast
cancers TP53 is not the actual target of LOH affecting the 17 p
subtelomeric region. To ascertain whether adjuvant CT in a set of
patients could have influenced the results as a confounding variable,
we examined the frequency of deletions in tumours of treated and
untreated patients. LOH data were available for 35 tumours of
patients who received adjuvant CT. No significant difference in the
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Table 3 Univariate analysis of prognostic categorized variables in 143
breast cancer patients: disease-free survival (DFS), overall survival (OS)
P-valuesa
Variableb DFS OS
T (≤ 2 cm vs > 2 cm) 0.007 0.002
N (N– vs N+) 0.001 0.003
ER (ER– vs ER+) 0.4 0.1
BrdU (low vs high) 0.002 0.002
Ki-67 (low vs high) 0.002 0.001
Chromosome 17p13.3 (normal vs LOH) 0.004 0.007
P53 mutations (normal vs mutated) 0.1 0.2
aBy Log-rank test. bT: tumour size; N: lymph nodes; ER: oestrogen receptors.
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Figure 1 Idiogram of the short arm of chromosome 17 showing the map
order of the markers (not in scale). The minimal region of loss (MRL) and the
genetic distances are indicated
Figure 3 Kaplan–Meier disease-free (A) and overall (B) survival curves
comparing patients with tumours showing LOH and a heterozygous status of
the 17p13.3-ter region. Significance values by log-rank test are indicated
Figure 2 Autoradiograms from Southern blot analysis demonstrating a loss
of heterozygosity (A), an uninformative tumour (B) that turned out deleted
with the microsatellite marker D17S379 (C)
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B
Adistribution of allele losses was observed between the two groups
(Table 2), so adjuvant CT could not have introduced a significant bias
on life-table estimates.
Survival analysis
LOH of chromosome 17p13.3-ter, lymph node status, tumour size,
S phase and Ki-67 all were predictive of disease-specific, relapse-
free and overall survival; ER and TP53 gene point mutations were
not (Table 3). Analysis of DFS (Figure 3A) showed that patients
bearing tumours with a chromosome 17p13.3-ter LOH had a
significantly higher probability of relapse than those with tumours
that had retained the same chromosome region (P = 0.004). By the
end of the study after a median follow-up duration time of 6.1
years (range 0.7–8.6 years) among 78 patients with heterozygous
tumours the rate of recurrence was 16.6%, while 36.9% of 65
patients with tumours affected by 17p13.3 LOHs had a relapse. In
addition 17p13.3-ter LOH appeared to be a good predictor of OS
(P = 0.007). Among 73 patients with tumours showing a normal
status of chromosome 17p13.3-ter, the death rate was 12.3% while
32.2% of 62 patients with tumours carrying LOHs died within 8
years (Figure 3B). Log-rank analysis on a subset of 82 patients,
whose tumours were informative for the 17p telomeric markers
and could be tested for TP53 point mutation of exon 5, 6, 7 and 8,
have shown that while TP53 status, in our hands, did not emerge as
significant prognostic indicator (P = 0.1) 17p13.3-ter LOH main-
tained its association both with DFS (P = 0.01) and OS (P = 0.03)
(data not shown). Genetic data were available for 65 of 68 axillary
node-negative patients; the number of events, however, were
insufficient for demonstrating any prognostic significance of the
17p13.3-ter LOH (P = 0.2).
Multivariate analysis
Even though the aim of our study was not the identification of a
new prognostic factor, we attempted to compare the predictive
power of 17p13.3-ter LOH with other clinical and biological
factors characterizing breast cancer. By proportional hazards
regression analysis, using as covariate six other unbiased explana-
tory variables known to have prognostic significance, 17p13.3-ter
LOH have shown an independent hazard ratio for DFS, with a
relative risk (RR) of recurrence below that of lymph node status
(Table 4). By stepwise regression analysis, performed with a
model that takes in account the same concomitant variables,
17p13.3-ter LOH emerged as a significant prognostic factor for
DFS (P = 0.01) while TP53 was removed from the procedure. For
OS, on the other hand, following stepwise selection 17p13.3-ter
LOH did not maintain its significance (P = 0.06) although its prog-
nostic power was still higher than the TP53 mutational status (2.51
vs 1.12 RR).
DISCUSSION
In our study, breast cancer specimens of 152 patients were exam-
ined for LOH of the short arm of chromosome 17, at band 13.3-ter.
The high frequency (45.5%) of this genetic alteration in breast
tumours and its association with cell proliferation suggest that the
17p13.3-ter locus is likely to include specific target genes whose
inactivation contributes to tumour development or progression.
We and others (Merlo et al, 1994) have provided evidence
suggesting that these genes are distinct from TP53 and are located
within the distal portion of the 17p chromosome arm. The
observed 17p loss does not reflect a general telomeric instability
of chromosome arms (White et al, 1996). The frequency of
17p13.3-ter LOH reported here may actually be an underestimate
of the prevalence of breast cancer allele losses at this locus. Since
in the present study no microdissection was attempted, LOH might
have been masked by the presence of normal cells in tumour
samples. In addition, D17S5 and D17S34/ABR cover 3 Mb of
DNA and do not detect interstitial deletions affecting smaller
portions of the chromosome arm bordered by these markers;
therefore the true extent of this chromosomal alteration is still
unknown. We tried to address the question in a previous report
(Stack et al, 1995) using a larger number of microsatellites
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Table 4 Multivariate analysis: proportional hazards regression, Cox model
DISEASE-FREE SURVIVAL
Covariate RR 95% Confidence P-value
interval
T (≤ 2 cm vs > 2 cm) 1.1 (0.3–3.8) 0.7
N (N– vs N+) 6.3 (1.3–29.6) 0.004
ER (ER– vs ER+) 1.0 (0.3–3.5) 0.5
BrdU (low vs high) 2.0 (0.5–8.1) 0.1
Ki-67 (low vs high) 1.1 (0.2–4.3) 0.2
Chromosome 17p13.3 LOH (normal vs LOH) 3.1 (0.9–10.4) 0.01
TP53 mutation (normal vs mutated) 1.6 (0.5–5.1) 0.2
OVERALL SURVIVAL
T (≤ 2 cm vs > 2 cm) 1.3 (0.3–5.0) 0.7
N (N– vs N+) 4.9 (1.0–24.3) 0.02
ER (ER– vs ER+) 0.6 (0.1–2.6) 0.4
BrdU (low vs high) 2.6 (0.5–12.9) 0.03
Ki-67 (low vs high) 1.4 (0.2–6.9) 0.6
Chromosome 17p13.3 LOH (normal vs LOH) 2.5 (0.6–9.5) 0.06
TP53 mutation (normal vs mutated) 1.1 (0.2–4.2) 0.6
RR = relative risks of relapse or death. T: tumour size, N: lymph nodes, ER: oestrogen receptors.spanning the same chromosome band. By these means we were
able to identify a distal region in which the frequency of loss was
close to 70%; the data collected, however, are at the present insuf-
ficient for accurate survival analysis. Although the correlation of
17p13.3 LOH with prognosis have been seen by others in breast
cancer (Nagai et al, 1994) an association of this genetic alteration
with OS has never been previously investigated. Our results
provide evidence that 17p subtelomeric lesions in breast tumours
can predict disease-specific survival and, therefore, are associated
with a more malignant phenotype. The lack of effect on outcome
of 17p13.3 LOH in node-negative patients needs comment. It
might be accounted for in part by the small number of observations
available for this subset of patients. As shown in another report
(Sato et al, 1990) no association was observed between 17p13.3
LOH and lymph node status in our panel of breast cancers.
Tumours of node-negative patients seem not to be genetically
different from breast carcinomas of patients with lymph node
involvement at the time of diagnosis. This notion is supported by a
meta-analysis (Mittra and MacRae, 1991) that demonstrates how
detection of axillary node metastasis is merely the consequence of
a delayed diagnosis and not an indication of actual biological char-
acteristics of tumour tissue. The hypothesis being tested in our
study was that breast carcinomas with allele losses at a specific
telomeric region of chromosome 17p13.3 could be associated with
a diminished survival and, therefore, a more aggressive tumour
phenotype. The present report is consistent with this hypothesis
and supports the conclusion that a tumour suppressor gene
involved in breast cancer, and distinct from TP53, exists on chro-
mosome 17p13. In fact our data fail to demonstrate any predictive
power of TP53 point mutations when they are tested, by multi-
variate analysis, together with cell kinetics and 17p13.3 LOH. Of
course we recognize that, since SSCP is only a screening test, our
results might have been influenced by the methodology used for
the detection of point mutations. However, several data support the
belief that TP53 might not play a critical role in breast cancer.
More than 70% of breast tumours have no TP53 mutation and the
frequency of LOH at the TP53 locus (17p13.1) is low (23%)
(Merlo et al, 1994). The most extensive molecular study on TP53
(Sjögren et al, 1996), based on complementary DNA analysis of
more than 300 tumours, have brought arguments in favour of an
association between p53 alteration and outcome. Its prognostic
power, however, was not tested against other genetic alterations.
Moreover, an experimental study has shown that suppression of
tumorigenicity in breast cancer cells does not necessarily require
the transfer of a wild-type p53 gene (Theile et al, 1995). In contrast
the role of 17p13.3-ter LOH in breast cancer is stressed by recent
evidence suggesting that these chromosomal alteration can occur
even in premalignant lesions such as mammary atypical hyper-
plasias and ductal carcinomas in situ, in which the rate of allele
losses have been reported to be higher than 35% (Radford et al,
1995).
Of course the association of LOH of 17p13.3-ter with malig-
nancy only provides circumstantial evidence but not formal proof
of the presence of a tumour suppressor gene. The smallest
common region of allelic loss on 17p defined by the markers used
in our study harbours a number of recently cloned putative tumour
suppressor genes. L132/Rox, identified by marker D17S379, has a
helix–loop–helix structure characteristic of many transcription
factors and binds DNA by forming heterodimers with Max
(Meroni et al, 1997). OVCA1 and OVCA2 have been isolated
from a cosmid clone, containing the closely linked marker D17S5,
that spans a minimal region of allele loss in ovarian cancer
(Schultz et al, 1996). The HIC-1 gene has been cloned from a
region flanking the D17S5 marker frequently hypermethylated in
multiple common types of human cancers, including breast cancer
(Makos et al, 1995). The CRK oncogene was originally identified
as a transforming component of the avian sarcoma virus CT10.
ABR shows homology to BCR, a gene involved in the
Philadelphia chromosome translocation in chronic myeloid
leukaemia (Heisterkamp et al, 1993). D17S34 is actually located
closer to ABR than to CRK, which is over 400 Kb proximal to this
marker (Morris et al, 1995). Loss or inactivation, through somatic
mutation, of a gene (or genes) mapping on the distal region of the
17p chromosome appears to be a crucial event in the development
and progression of sporadic breast cancer as it is able to affect the
malignant behaviour of tumours.
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